Vimpat®

Europe

In the European Union, Vimpat® (lacosamide) (film-coated tablets, syrup and solution for infusion) is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.

Vimpat® is indicated as adjunctive therapy

• in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Prescribing information Europe

• SmPC Vimpat® (EU). Sourced from www.ema.europa.eu.

Related websites

• Vimpat® product website (for US residents only)

USA

In the US, Vimpat®  (lacosamide) CV is indicated

• for the treatment of partial-onset seizures in patients 1 month of age and older
• as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

In the U.S., Vimpat® is available as oral tablets, oral solution and injection.

Other countries

For availability of Vimpat® in other countries, please consult our local websites.